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A highly potent human antibody neutralizes
dengue virus serotype 3 by binding across
three surface proteins
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Dengue virus (DENV) infects B400 million people annually. There is no licensed vaccine or
therapeutic drug. Only a small fraction of the total DENV-specific antibodies in a naturally
occurring dengue infection consists of highly neutralizing antibodies. Here we show that the
DENV-specific human monoclonal antibody 5J7 is exceptionally potent, neutralizing 50% of
virus at nanogram-range antibody concentration. The 9 Å resolution cryo-electron micro-
scopy structure of the Fab 5J7–DENV complex shows that a single Fab molecule binds across
three envelope proteins and engages three functionally important domains, each from a
different envelope protein. These domains are critical for receptor binding and fusion to the
endosomal membrane. The ability to bind to multiple domains allows the antibody to fully
coat the virus surface with only 60 copies of Fab, that is, half the amount compared with
other potent antibodies. Our study reveals a highly efficient and unusual mechanism of
molecular recognition by an antibody.
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T
he global incidence of dengue virus (DENV) infection has
increased drastically in recent decades. It is estimated that
about 400 million people worldwide are infected with
DENV annually, resulting in B100 million cases of dengue fever
and 21,000 deaths1,2. DENV are mainly detected in the tropical
and sub-tropical regions around the world, with high incidence
reported from the Americas, Eastern Mediterranean, Southeast
Asia and the Western Pacific regions. DENV is one of the most
important arthropod-borne virus that targets humans. It is
transmitted to humans by the bite of infected Aedes aegypti or,
less frequently, Aedes albopictus mosquitoes3.
DENV belongs to the Flaviviridae family, along with other
major human pathogens such as West Nile virus, Japanese
encephalitis virus and yellow fever virus. There are four DENV
serotypes (DENV1–4)4,5. Patients infected with any one of the
four serotypes can display a spectrum of symptoms, ranging from
being asymptomatic to showing mild dengue fever, to the severe
dengue haemorrhagic fever or dengue shock syndrome6. An
initial primary infection by a DENV serotype induces life-long
protection against the homologous serotype7. However, in a
secondary infection by a different DENV serotype, the formation
of non-neutralizing complex of DENV with cross-reactive
antibodies from the previous infection may enhance viral
infection through a mechanism known as antibody-dependent
enhancement8. This may lead to an increased risk of developing
the severe dengue haemorrhagic fever. This suggests that a safe
and effective vaccine would have to include only neutralizing
epitopes from all four DENV serotypes. Therefore, mapping of
these sites on E protein, recognized by highly neutralizing human
antibodies, is crucial for vaccine development.
Inside the DENV particle lies the 11-kb single-stranded positive
sense RNA genome complexed with capsid protein. The
nucleocapsid is surrounded by a bilayer lipid membrane and on
the outside of the membrane are the 180 pairs of envelope (E) and
membrane (M) proteins9,10. The E and M proteins are arranged
with icosahedral symmetry with each asymmetric unit containing
three pairs of E and M heterodimers. The E proteins exist as head-
to-tail homodimers. Three of these dimers lie parallel to each other
forming a raft9–11. The E protein ectodomain consists of three
domains: DI, DII and DIII12–14. E protein plays an important role
in virus entry into host cell as it binds to receptors and facilitates
fusion of the virus to the endosomal membrane15–17. Neutralizing
antibodies principally target the E protein18.
Mouse monoclonal antibody (MAb) studies showed that the
most potent antibodies bind to DIII19–21, whereas in humans very
few antibodies are directed to this region22–25. In a naturally
occurring primary dengue infection, a large fraction of the antibody
repertoire consists of cross-reactive and poorly neutralizing
antibodies, with only a small fraction showing serotype-specific
and highly neutralizing properties26–28. The highly neutralizing
serotype-specific human MAbs (HMAbs) generally recognize
quaternary structure-dependent epitopes on the virus surface26,29.
Here we show that HMAb 5J7 is a very potent antibody that
can neutralize DENV3 at nanogram-range concentrations. We
determine the cryo-electron microscopy (cryo-EM) structure of
DENV3 complexed with Fab 5J7 to 9 Å resolution and show that
one Fab molecule binds across three E proteins and engages only
domains that are critical for infection. This mode of binding has
not been observed previously in any virus system and the results
showed the structural basis of neutralization by extremely potent
antibodies.
Results
HMAb 5J7 prevents virus attachment. We have previously
shown that HMab 5J7 exhibited cross-reactive binding to all four
DENV serotypes in an enzyme-linked immunosorbent assay
(ELISA) and yet strongly neutralized only DENV3 virions26,30.
To provide further support to the type 3-specific binding pattern
and the potency of HMAb 5J7, we repeated the binding assays
here with intact particles or recombinant E (rE) proteins, and also
the neutralization assays as an independent laboratory. The assays
showed that HMAb 5J7 is a highly potent DENV3-specific
HMAb (50% neutralization concentration [neut50] value of
0.005 mg ml 1) (Fig. 1a and Supplementary Fig. 1). HMAb 5J7
binds the whole DENV particle at a much higher affinity than the
soluble form of the rE protein expressed in insect cells
(Supplementary Fig. 1). The Fab fragment is also strongly
neutralizing (neut50¼ 0.041 mg ml 1) (Fig. 1b), although
eightfold poorer than the full-length antibody. The higher
potency of the whole antibody compared with
Fab fragment could be due to several reasons, including (1)
higher avidity of the bivalent form of antibody, (2) the ability of
the bivalent antibody to aggregate virus particles31, or (3)
increased steric hindrance of virus–host interactions (such as
receptor binding or interaction of virus with the endosomal
membrane during fusion) due to the larger size of the whole
antibody.
The most common way to determine whether the antibody
inhibits virus-receptor binding or a postattachment step of the
infection is to compare neutralization curves when antibody is
mixed with the virus before or after virus binding to cells at 4 C
(Fig. 1c). The assumption is antibodies that inhibit receptor
binding will not have a neutralizing effect on virus that has
already bound to its receptor. However, this assumption may not
be true, as high-affinity antibodies may displace the virus that is
already complexed to a low-affinity receptor. To test this, we used
real-time reverse transcriptase–PCR (RT–PCR) to quantify the
remaining virus on the cell surface, which were exposed to
antibodies pre- and postvirus attachment to cells. The plaque
number of pre-and postattachment neutralization tests showed
no difference (Fig. 1c); this would suggest that the antibody
inhibit a postattachment step of the infection. On the contrary,
the RT–PCR results (Fig. 1e) suggest that the antibody displaced
the virus that has already bound to the cell receptor, therefore
emphasizing that deriving the mechanism of neutralization by
just conducting the neutralization tests alone would be mislead-
ing. RT–PCR result showed that the virus exposed to antibody
before virus attachment to cells has decreasing amount of virus
on cell surface with increasing concentrations of antibodies. This
trend is also detected when the virus is exposed to antibodies after
it has attached to cells, indicating that virus had been removed
from the cell surface by antibodies. Notably, the HMAb 5J7
seemed to be more efficient in removing the virus, when mixed
with virus after it had attached to cells than before attachment
(Fig. 1d,e). Overall, the RT–PCR results suggest that the antibody
binds either directly or very close to the receptor-binding site on
the virus. In addition, HMAb 5J7–virus affinity is much higher
than the virus–receptor affinity, thus displacing the virus on the
cell surface.
In addition to inhibition of receptor binding by HMAb 5J7, the
antibody can also prevent the virus entry into cells at a
postattachment step. When 5J7 is first added to the virus and
then incubated with cells (preattachment), the antibody reduces
the number of bound virus particles but there is still a substantial
fraction of virions (B50% at 10 ngml 1) that bind to the cells
(Fig. 1d). The preattachment neutralization test (Fig. 1c) showed
that neut50 is about 0.56 ng ml 1 and neut100 at 10 ngml 1. The
fact that 10 ng ml 1 results in 100% neutralization (as shown in
the neutralization test; Fig. 1c) despite substantial virus binding to
cells (Fig. 1d) indicated that this MAb can block infection after
virus attachment to cells.
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Mature DENV3 and DENV3–Fab 5J7 complex structures. The
cryo-EM structure of DENV3 complexed with Fab fragments of
HMAb 5J7 was determined to 9 Å resolution (Fig. 2a,b). The
shapes of the transmembrane helices and the domain boundaries
of E protein and Fab molecules were well resolved (Fig. 2c).
At full occupancy, 60 copies of Fab 5J7 bound to the virus
surface.
The footprint of HMAb 5J7 on the E protein can be identified
by fitting the crystal structure of the DENV3 E ectodomain (PDB
accession code 1UZG)13 and the Fab homology model into the
cryo-EM map. To increase the precision of the fit of E protein
structures on DENV3 surface, we also determined the cryo-EM
structure of uncomplexed mature DENV3 to 6 Å resolution
(Supplementary Fig. 2a,b). The densities of the helical ridges on
the transmembrane helices are visible (Supplementary Fig. 2d).
DENV3 used in this structure determination was grown in C6/36
cells at 28 C and kept at 4 C before freezing on cryo-EM grids.
As the DENV3-Fab 5J7 complex was formed at 37 C, we also
determined a 7-Å resolution cryo-EM structure of the
uncomplexed mature DENV3 that had been exposed to 37 C
for 30 min and incubated at 4 C for 2 h before freezing
(Supplementary Fig. 3a,b). The DENV3 E protein has two
residues deleted in the EoFo loop (Supplementary Fig. 2e)
compared with DENV1, 2 and 4. Superposition of cryo-EM
structures of uncomplexed DENV3 at 28 C and 37 C showed
similar structures (Supplementary Fig. 3c). Therefore, unlike the
DENV2 New Guinea C strain32,33, the E protein layer of the
uncomplexed DENV3 863DK strain does not undergo
irreversible conformational changes when exposed to 37 C
(Supplementary Figs 3 and 4).
A homology model of the variable region of the Ab heavy and
light chains (Fig. 2c), and the 6-Å resolution cryo-EM structure of
the uncomplexed DENV3 863DK strain were then fitted into the
9-Å cryo-EM Fab-DENV structure. The DENV3–Fab 5J7
complex structure displayed a very similar E protein conforma-
tion as uncomplexed DENV3. Superposition of the Ca chains of
E proteins of the Fab complex and uncomplexed cryo-EM
structures showed a root mean square deviation value of 1.08 Å.
This shows that binding of HMAb 5J7 did not induce significant
structural rearrangement of the E proteins on virus surface.
Epitope recognized by HMAb 5J7. As side-chain densities are
not resolved in the 9 Å resolution cryo-EM Fab 5J7–DENV3 map,
interacting residues between Fab and E proteins were identified
by observing pairs of Ca atoms within a distance of o8 Å. In
addition, the ability of these residues to form hydrogen bonds or
hydrophobic interactions was also considered. One Fab molecule
bound to three E proteins (molecules (mol) A, B and B0 of the E
protein raft) (Fig. 3a). The footprint of the antibody covers a
surface area of B1,500 Å2 of which B74% (B1,100 Å2) is on
mo) A (Fig. 3a). The large area of contact on a single E protein
molecule is consistent with the ability of HMAb 5J7 to bind to rE
protein26 at high antibody concentrations (Supplementary Fig. 1).
The interacting surface on the Fab 5J7 molecule comprises five
of the six common complementary determining regions: L1
(residues 35–38), L3 (residues 99–101), H1 (residues 35–38), H2
(residues 59–62) and H3 (residues 105–113) with the addition of
H2–3 region (residues 81–84) (Table 1). In most antibodies, the
H2–3 region is located on the outer part of complementary
determining regions and usually does not interact with the
antigen. However, in Fab 5J7, the H2–3 region interacted with
DIII of E protein mol B. A total of 15 amino acid residues from
the variable region of the heavy chain interacted with E proteins.
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Figure 1 | Neutralization of DENV3 infection by HMAb 5J7 in Vero cells. Neut50 value of (a) HMAb 5J7 and (b) its Fab fragment to DENV3 in Vero cells
was 0.005 and 0.041mg ml 1, respectively. Fab fragment, although strongly neutralizing, required B8.2 times higher concentration for neutralization
compared with the whole antibody. (c) HMAb 5J7 had similar neutralization activities when exposed to virus before or after attachment to Vero cells.
Amount of virus on the cell surface, as detected by RT–PCR, when exposed to antibodies (d) before and (e) after the virus was allowed to attach to cells.
The result showed that high concentrations of antibodies are required to prevent attachment of virus to cell surface when virus is exposed to HMAb 5J7
before cell attachment (d). On the other hand, HMAb 5J7 seemed to be able to strip the virus off the cell surface efficiently when the virus is exposed to
the antibodies post attachment (e). Values are mean±s.d. Experiments were repeated at least twice.
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In comparison, only six amino acids from the L chain are
involved.
The 5J7 epitope probably consists of 31 amino acid residues
(Fig. 3a). Interactions between Fab 5J7 and E protein on DENV3
consist of hydrogen bonds, salt bridges and hydrophobic
interactions. For example, R38 (light chain) and R113 (heavy
chain) of Fab 5J7 interact with E123 and E126 of E protein,
respectively. A slightly negatively charged patch formed by T35,
S37, S82 and S84 of the heavy chain interacted with a positively
charged patch formed by K307 and K308 of the E protein
(Fig. 3b). Fab 5J7 binds to the DI–DII hinge region of mol A, DIII
of mol B and the tip of DII of mol B0, which contains the fusion
loop (Fig. 3a and Table 1). The three E protein domains
comprising the epitope are each crucial for discrete components
of the mechanisms underlying DENV attachment and entry. DIII
is involved in receptor binding and fusion34,35. DI–DII hinge is
important for movements of the E protein during virus entry. The
DII fusion loop is essential for binding to the endosomal
membrane during fusion17. Previous study26 also identified parts
of the 5J7 epitope by sequencing neutralization escape mutant.
The escape mutant contains a lysine insertion in the DI–DII
hinge region between residues Q269 and N270, consistent with
the epitope identified by cryo-EM.
Another site on the E protein raft that is similar to the
quaternary structure-dependent epitope recognized by HMAb 5J7
is located on mols B, C and A0 (Fig. 3c). However, antibody
binding was not detected in this area. Fabs bound to the epitope
on mols A, B and B0 would not hinder the binding of Fabs to this
second site, as there is enough space between the Fabs on those
two sites (Supplementary Fig. 5). Superposition of the Fab-E
protein structure onto this site in the 6-Å resolution uncomplexed
DENV3 structure (Supplementary Fig. 3) showed that the bc loop
of mol A0 is elevated compared with that in mol B0 (Fig. 3c). The
elevated position resulted in a distance of B3 Å between Ca
chains of the bc loop of mol A0 and the heavy chain of the Fab
molecule. This would probably result in side-chain clashes, thus
preventing antibody binding.
Discussion
HMAb 5J7 binds to DENV3 specifically. Comparison of the
DENV3 amino acid sequence (Fig. 3a) and surface electrostatic
potential (Fig. 4) of the regions corresponding to the epitope with
the other serotypes showed that some residues on DENV1, 2 and
4 have opposite charges. For example, in DENV3, positions 123
and 126 contained negatively charged glutamate residues that
interact with a positive patch on Fab 5J7, whereas the same
positions in DENV2 are occupied by positively charged lysine
residues. Other residues corresponding to the 5J7 epitope in
DENV1, 2 and 4 also have different hydrophobicity character-
istics compared with DENV3. For instance, position 123 of
DENV4 is occupied by glycine, thus losing the ability to form a
salt bridge with R38 of the Fab molecule. In DENV3, position 55
(Thr) and 307 (Lys) formed hydrogen bonds with residues K107
and S82/S84 of the Fab molecule, respectively. On the other hand,
DENV1 and DENV4 at position 55 and also in DENV2 at
position 307 contained hydrophobic residues. In addition,
DENV1, 2 and 4 E proteins have two additional amino acids
between residues 156 and 157 (EoFo loop) (Supplementary
Fig. 2e). As the Fab heavy chain binds to a nearby residue
(Q148) in this loop, the differences in the length of EoFo loop and
the amino acid sequence variation of the epitope may determine
the serotype specificity of HMAb 5J7
RT–PCR quantification of virus that were exposed to HMAb
5J7 after virus binding to cells showed that the antibody is able to
remove virus from cell surface, therefore suggesting that the
antibody is binding directly or close to the receptor binding site.
Interestingly, comparing the amounts of virus on the cell surface
that are exposed to antibodies pre- and post attachment suggests











Figure 2 | The cryo-EM structure of DENV3 complexed with Fab 5J7. (a) The 9-Å cryo-EM map of DENV3 complexed with Fab 5J7. The black triangle
and numbers represent an icosahedral asymmetric unit and the icosahedral vertices, respectively. (b) Cross-section of a quarter of the cryo-EM map.
Cryo-EM map is coloured by radii: red-to-yellow gradient (0–160 Å), green (160–200 Å), cyan (200–240 Å) and blue (240–295 Å). (c) The fit of
transmembrane a-helices (left) and ectodomain (centre) of E proteins and the heavy and light variable region of antibody (right) into the density map.
E protein DI, DII and DIII are coloured in red, yellow and blue, respectively. The stem and transmembrane region of the E protein is coloured in blue,
whereas the same region in the M protein is coloured in salmon (left panel).
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Figure 3 | Fab 5J7 binds to three E proteins. (a) 5J7 epitope on an E protein raft. The three E protein molecules in an asymmetric unit are labelled as A, B
and C, respectively, and those in the neighbouring asymmetric unit, A0, B0 and C0 , respectively. The residues on the E protein that interact with heavy and
light chains of the Fab are shown as green and magenta spheres, respectively. Bottom panel: comparison of epitope to the other DENV serotypes. The
secondary structures are indicated above the amino acid sequence. The amino acid residues that interact with the heavy and light chain of Fab 5J7 are
highlighted in the same colouring scheme as above. The individual E protein molecules in the two asymmetric units of the raft where the epitope residues
belong are also indicated. (b) Open-book representation of the electrostatic potential of the interacting residues on the E proteins (left) and Fab 5J7 (right).
Positive, negative and neutral charges are coloured in blue, red and white, respectively. Boundaries of the interacting interface on antibody and epitope are
shown as cyan lines. The border between the heavy and light chains of the antibody paratope and its corresponding footprint on the epitope are coloured
yellow. Interacting residues that show charge complementarity between the epitope and Ab are indicated. Residues on heavy and light chains are labelled
with green and magenta colour, respectively. (c) Fab 5J7 does not bind to a similar epitope on the E protein B-C-A0 mols (left figure, dotted box) probably
due to the difference in the conformation of the bc loop in DII. Superposition of the 5J7 epitope (spheres) on E protein mols A-B-B0 (grey), onto molecules
B-C-A0 on the 6 Å resolution, uncomplexed DENV3 cryo-EM structure (left). Enlarged view (right) showed that the bc loop on mol B0 of the epitope on A-B-
B0 (grey spheres) is shifted in mol A0 (black arrow) of the B-C-A0 molecules. The elevated position of the bc loop in mol A0 may lead to side-chain clashes
with the heavy chain of the Fab molecule (green), thus preventing antibody binding.
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cell surface when it has already bound to its receptor (Fig. 1e). As
HMAb 5J7 binds across three E proteins, any motions between
these molecules may reduce antibody binding. Our uncomplexed
DENV3 structure represents the structure that was incubated at
37 C for 30 mins and then 4 C for 2 h before freezing. It did not
show any structural difference compared with the sample that
was grown at 28 C. This finding suggests that the E proteins on
DENV3 do not undergo temperature-irreversible conformational
change, as observed in DENV2 (refs 32,33). However, it is still
possible that the E proteins have small conformational changes
when kept at 37 C, thus lowering the binding of HMAb 5J7 to
virus before it attaches to cells. When the virus attaches to a
receptor, this engagement may stablize the virus quaternary
structure, thus improving the binding efficiency of the antibody
consistent with our RT–PCR results. The DENV receptor(s) on
Vero cells, which were used in the RT–PCR pre- and
postattachment assays, are largely unknown. One receptor that
has been identified previously is the carbohydrate recognition
domainsof the dendritic cell-specific intercellular adhesion
molecule 3-grabbing non-integrin (DC-SIGN). One molecule of
DC-SIGN binds across two N67 glycosylation sites from
neighbouring E proteins (mol A and B0) (Fig. 5)36. Super-
position of the DENV–carbohydrate recognition domain and
DENV3–Fab 5J7 complex structures showed a clash between DC-
SIGN and the heavy chain of Fab 5J7, suggesting that the binding
of antibody may prevent or compete with the virus from
interacting with the DC-SIGN receptor (Fig. 5) on dendritic cells.
HMAb 5J7 can also block infection at a step post virus
attachment, probably fusion of virus to the endosomal mem-
brane. The two Fab molecules on an E protein raft can lock four E
proteins (mols A, B, A0 and B0) into a rigid configuration (Fig. 3a).
E proteins on the uncomplexed DENV undergoes structural
change when exposed to low pH environment in the endosome
during fusion17. This involves the reorganization of the E proteins
from a dimeric structure to a trimeric one17,37. In the Fab 5J7-
DENV structure, only the E protein mols C remain unbound by
Fabs, suggesting that the switch to trimeric structure may not be
possible.
Recognition of quaternary structure-dependent epitope is
common among some strongly neutralizing HMAbs26 and this
could be due to peculiar arrangement of the E proteins lying flat
to each other on the virus surface. The binding of antibodies
across the E proteins will then prevent structural rearrangment
necessary for infection such as fusion. Structures of HMAbs that
bind the E DI–II region of DENV1 (1F4 and 14c10)29,38 and
West Nile virus (CR4354)39 had been determined previously
(Fig. 6). These antibodies are serotype specific and bind to
quaternary structure-dependent epitopes. HMAbs 14c10 and
CR4354 bind to overlapping epitopes on DENV1 and West Nile
virus, respectively (Fig. 6c,d). The epitopes are located on DI and
DI–II hinge region of an E protein and DIII of an adjacent E
Table 1 | Interacting residues between the Fab 5J7 and the
E proteins on a raft.
HMAb 5J7 E protein mols HMAb 5J7 E protein mols
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Figure 4 | Comparison of the electrostatic charges of the epitope across
DENV1–4. Electrostatic potential surfaces of a raft consisting of two
icosahedral asymmetric units are shown. Positive and negative charges are
shown in blue and red colours, respectively. The border of the 5J7 epitope is
outlined with a black line. The DENV structures used for the electrostatic
potential surface calculations are from PDB accession codes 4CCT
(DENV1), 3J27 (DENV2), 3J6S (DENV3) and 4CBF (DENV4).
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protein. Although HMAb 1F4 binds to the DENV1 particle but
not rE protein, the epitope is located on a E protein monomer at
the DI–II hinge (Fig. 6b). Binding of HMAb 1F4 is highly
sensitive to the DI–DII hinge angle. This is consistent with the
preference of the Ab to bind to the E DI–DII hinge on the virus
surface but not to the same region on soluble rE protein, as the
hinge angle of the DI–DII region is highly variable in soluble rE
protein. These HMAb-flavivirus cryo-EM structures showed that
120 molecules of Fab bind to virus surface at full occupancy.
HMAb 5J7, on the other hand, binds to three E proteins at the
same time, therefore requiring only 60 copies for full occupancy,
consistent with its higher neutralization potency. This finding of a
single Fab simultaneously engaging three functionally significant
E protein domains each on a different E protein molecule has not
been observed in antibodies binding to other viruses. In
conclusion, the very low quantity of Ab required for
neutralization and the unique mechanism of binding and
neutralization mediated by interaction with three critical E
protein domains make HMAb 5J7 a potential therapeutic
candidate molecule. The epitope also posed as an interesting
target for structure-based rational vaccine design.
Methods
Virus sample preparation. Primary isolate DENV-3/SG/05K863DK1/2005 (ref.
40) and the reference strain DENV3 CH53489 (genotype 2, a Bangkok isolate that
was isolated by USAMC-AFRIMS in 1973) were used in this study. DENV3
CH53489 was used in all the experiments except for the cryo-EM studies, where the
primary isolate was used. Neutralization test using HMAb 5J7 showed that the
antibody strongly neutralized both strains.
The methods to produce and purify virus had been described previously9.
Briefly, DENV3 were grown in A. albopictus C6/36 cells. Cells were grown to
B80% confluency before inoculating with DENV at a multiplicity of infection of
0.1. Inoculated cells were incubated at 28 C for 4 days. The virus-containing
supernatant was harvested and clarified by centrifugation at 9,000 g for 30 min.
Virus in supernatant was precipitated by using 8% w/v polyethylene glycol 8000 in
NTE buffer (10 mM Tris-HCl pH 8.0, 120 mM NaCl and 1 mM EDTA). The pellet
was collected by centrifugation at 14,300 g. Virus was resuspended in NTE buffer
and then further purified by centrifugation using a 24% w/v sucrose cushion and
then a linear 10% to 30% w/v potassium tartrate gradient. The virus band was
collected, buffer exchanged into NTE buffer and concentrated using an Amicon
Ultra-4 centrifugal concentrator (Millipore) with a 100-kDa molecular-mass
cut-off filter. All steps of the purification procedure were done at 4 C. Purified
virus was kept at 4 C before freezing on cryo-EM grids. Coomasie-stained
SDS–PAGE gel was used to assess the purity of the virus preparation. A faint band
of the 25-kDa premembrane protein was detected, indicating a slight
contamination with immature virus particles. Concentration of the envelope
protein was estimated by comparing the band with the different concentrations of
BSA protein standard band.
DENV3 neutralization assays. The flow cytometry-based neutralization assay
with Vero-81 cells were conducted using a similar protocol similar to the neu-
tralization assay with U937þDC-SIGN cells described in Krauss et al.41 Briefly,
1.25 104 cells per well were plated in a 96-well plate 48 h before conducting the
experiment. The 5J7 whole antibody (mAb) or 5J7 Fab were serially diluted and
incubated with DENV3 (CH53489) for 1 h at 37 C under 5% CO2. The mixture
was then added to the 96-well plate containing Vero-81 cells. Two hours post
infection, the cells were washed twice with fresh infection media and incubated at
37 C under 5% CO2. At 24 h post infection, the cells were washed, fixed,
permeabilized and stained for DENV E protein using 2H2 conjugated to Alexa
Fluor 488, and percentage of infected cells were measured using flow cytometry.
Sigmoidal neutralization curves were generated using GraphPad Prism 6.
ELISA assay to determine the serotype-specificity of HMAb 5J7. Fifty
microlitres of polyethylene glycol-precipitated virus was diluted in PBS and used to
coat Maxisorp ELISA plates (Nunc) overnight at 4 C. The wells were blocked using
300 ml of 5% (w/v) skimmed milk-PBS per well for 1 h. Fifty mirolitres of HMAb
5J7 at 5 mg ml 1 was applied to each well for 1 h at 37 C and the plates washed
thrice with PBS-Tween (0.1% v/v). This was followed by the addition of 50 ml of
goat anti-human IgG-horseradish peroxidise-conjugated antibody (Invitrogen,
1:2,000 v/v) for another hour at 37 C. Following a second wash with PBS-Tween,
detection was achieved using TMB chromogen substrate (Life Technologies) and











Figure 5 | Simultaneous binding of Fab 5J7 and DC-SIGN to DENV3
surface is unlikely to occur. Superposition of the carbohydrate recognition
domain (CRD) of DC-SIGN–DENV2 structure onto Fab 5J7–DENV3
structure showed the Fab 5J7 and DC-SIGN molecules clashed on the virus
surface. One DC-SIGN molecule binds across two adjacent N67 glycans on
the virus surface. Simultaneous binding of these molecules on the virus
surface is not possible, as the Fab and DC-SIGN molecules clashed. E
protein mols A, B and C are coloured in light grey and mols A0, B0 and C0 in
grey. The heavy and light chains of the Fab are coloured in green and
magenta, respectively. DC-SIGN is shown as a transparent orange surface.
The glycosylation sites on N67 are marked as red stars. Arrows indicate the





































Figure 6 | Comparison of quaternary structure-dependent epitopes on E
protein raft. Comparison of quaternary structure-dependent epitopes on E
protein raft bound by HMAbs (a) 5J7, (b) 1F4 (ref. 38) and (c) 14c10
(ref. 29) to DENV, and (d) HMAb CR4354 to West Nile virus (WNV)39.
Epitopes are represented as green spheres.
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ELISA assay to compare 5J7 binding to rE protein and virus particle. The
antigens used for the ELISA assay were from DENV3 strain CH53489. Intact
virions or rE protein (amino acids 1–395) were purified as previously descri-
bed23,42. HMAbs used in the assay were 1M7 and 5J7. 1M7 is a flavivirus cross-
reactive antibody that binds to a conserved epitope on the fusion loop of the rE
protein24. Mouse MAbs used in the assay were 4G2 and DV2-30. 4G2 is a flavivirus
cross-reactive antibody that binds to a conserved epitope on the fusion loop of the
rE protein43. DV2-30 is a DENV2 type-specific antibody that was used as a
negative control44. ELISA plates (Nunc 242757) were coated overnight at 4 C with
50 ng of virus or 100 ng E protein in carbonate buffer. Plates were washed and
blocked with 3% normal goat serum in PBS (blocking buffer). Antibodies were
serially diluted in blocking buffer and added to each well for 1 h at 37 C. The plates
were washed and then incubated with alkaline phosphatase-conjugated goat anti-
mouse or human IgG secondary antibodies for 1 h at 37 C. After a final wash step,
the plates were developed using p-nitrophenyl phosphate substrate and any colour
change was quantified with a spectrophotometer.
Pre- and postattachment neutralization assays. The pre- and postattachment
neutralization assays were conducted as previously described38. Briefly, for
preattachment neutralization assays, Vero-81 cells were grown in 24-well plates
and all reagents were cooled for at least 30 min at 4 C. Serially diluted 5J7 antibody
was combined with DENV3 virus and incubated at 4 C for 1 h. The mixture was
added to Vero cells and then incubated for 1 h at 4 C. One hour post infection, the
infected cells were washed three times with cold PBS, methyl cellulose was then
added and kept at 37 C for 4 days before fixing and staining the cells for DENV
foci. For postattachment neutralization assays, Vero-81 cells and other reagents
were prechilled at 4 C. DENV3 virus was added to Vero cells and incubated for 1 h
at 4 C. The virus-bound cells were then washed twice with cold PBS, serially
diluted 5J7 antibody was added to cells and further incubated for 1 h at 4 C. The
cells were washed once with cold PBS and incubated for another 4 days at 37 C.
The cells were then fixed and stained for DENV foci.
RT–PCR to quantitate virus on cell surface. The amount of DENV3 remaining
on the surface of Vero cells after 5J7 treatment was estimated by quantitative
RT–PCR as previously described45. In brief, DENV3 was mixed with different
concentrations of 5J7 before and after the virus attached to cells at 4 C. The cells
were washed and total cellular RNA was purified using TRIzol reagent
(Lifesciences), as described in the manufacturer’s instructions. Complementary
DNA was prepared using iScriptTM Reverse transcription supermix for RT–qPCR
kit (Bio-Rad), as described in the manufacturer’s instructions. The 20-ml reaction
contained 4 ml iScript RT supermix (5 ), RNA template (1 mg) and nuclease-free
water. The RT–PCR condition to synthesize the first strand of cDNA are: 25 C for
5 min for attachment of primers to template RNA), 42 C for 30 min for reverse
transcription and final 85 C for 5 min for reverse transcription inactivation.
Real-time quantitative PCR (qPCR) was performed using iQTM SYBRR Green
supermix kit (Bio-Rad) in a CFX 96 Real-Time System (Biorad), as per the
manufacturer’s instruction. The 20-ml, reaction contained 10 ml SYBR Green super
mix (2 ), 1.2 ml each of 10 mM forward (50-CAA TAT GCT GAA ACG CGA
GAG AAA-30) and reverse primers (50-AAG ACG TAA ATA GCC CCC GAC-30),
3 ml cDNA and 4.6 ml double-distilled H2O. The thermal profile for qPCR was 95 C
for 3 min, to activate the polymerase and denature DNA; this is then followed by 40
cycles of denaturation at 95 C for 10 s, annealing at 65 C for 10 s, extension at
65 C for 30 s. Glyceraldehyde-3-phosphate dehydrogenase was used as the
housekeeping gene to normalize samples (forward 50-CTGTTGCTGTAGCCA
AATTCGT-30 , reverse 50-ACCCACTCCTCCACCTTTGAC-30). The analysis of
relative levels of DENV3 RNA in different samples was performed by comparative
2-DDCT method46.
Cryo-EM image collection and processing. Purified virus was mixed with Fab
5J7 in the same molar concentration as the E protein in DENV3 and incubated at
37 C for 30 min followed by another 2 h at 4 C. The DENV3 control (without Fab
5J7) was also prepared in similar way, except it was incubated at two different
temperatures (4 C and 37 C) for 30 min. From this point onwards, in this study,
these samples are designated as DENV3 at 28 C (the temperature at which it was
grown) and DENV3 at 37 C, respectively. A 2.5-ml sample was transferred onto an
ultra-thin carbon-coated lacey carbon grid (Ted Pella) and blotted with filter paper
for 2 s before snap freezing in liquid ethane, using the FEI Vitrobot Mark IV.
Frozen grids were stored in liquid nitrogen temperature. The virus particles were
imaged using Titan Krios cryo-EM with field-emission gun operated at 300 kV.
Images were collected at nominal magnifications of 59 k (DENV3—Fab 5J7 com-
plex), 75 k (DENV3 at 28 C control) and 47 k (DENV3 at 37 C), with a total
electron dose of 18–20 e Å 2. The images were captured on a direct electron
detector (Falcon, FEI) for DENV3-Fab 5J7 and DENV3 at 37 C data sets, and a
Gatan charge-coupled device camera for DENV3 at 28 C data set with effective
pixel sizes of 1.37, 1.7 and 1.16 Å per pixel, respectively. Images showing strong
drift and astigmatism were discarded. In total, 254 (DENV3—Fab 5J7 complex),
836 (DENV3 at 28 C) and 138 images (DENV3 at 37 C) were selected with a
defocus range of 0.4–4.2, 1.1–3.5 and 0.8–3.2 mm, respectively, for further
processing.
Cryo-EM image reconstruction. The spiky-looking unbroken particles of the
DENV3-Fab 5J7 complex were selected manually, by using the e2boxer tool in the
EMAN2 (ref. 47) software package. In the control DENV3 at 28 C and 37 C,
smooth particles that represent the majority of the virus population were selected.
In total, 4,144 (DENV3–Fab 5J7 complex), 11,700 (DENV3 at 28 C) and 4,035
(DENV3 at 37 C) particles were used for reconstruction. The parameters of the
contrast transfer function for each micrograph were first automatically determined
by using the programme fitctf and then manually optimized using the ctfit
programme in EMAN48.
For the DENV3 at 28 C control, the cryo-EM map of DENV4 (Electron
Microscopy Database accession code EMD-2485) was used as an initial model. The
initial model was used in the orientation search of the particles that was carried out
using Multi-Path Simulated Annealing procedure49. Following the orientation
search, a three-dimensional reconstruction was done with make3d from EMAN. A
total of 6,800 particles was used in the reconstruction of the final map of DENV3
at 28 C.
For the DENV3 at 37 C control and also the Fab 5J7 complex, the cryo-EM
map of DENV3 at 28 C was used as an initial model. The final map of DENV3 at
37 C was reconstructed from 3,009 particles. For the reconstruction of the
DENV3–Fab 5J7 complex, the particles were initially treated as a homogenous
population but a medium resolution map (B15 Å) was obtained. The micrograph
of DENV3 at 28 C or 37 C controls showed that there are B20% of immature
particles. To reduce the influence of immature and unbound mature virus particles
in the Fab 5J7–DENV3 reconstruction, several cycles of reconstruction using
simultaneously three initial models—DENV3–Fab 5J7, DENV3 at 28 C and
immature DENV (Electron Microscopy Database accession number EMD-2141))
were done. From 4,144 particles, 2,047 particles (49%) were selected for three-
dimensional reconstruction of the DENV3–5J7 complex, whereas 863 (20.8%) and
731 (17.6%) particles were selected for mature and immature virus reconstruction,
respectively. This procedure allowed the identification of the likely unbound
mature and immature particles, and these particles were removed in subsequent
cycles of the DENV3–Fab 5J7 reconstruction. The final map of the DENV3–Fab
5J7 complex was reconstructed from 970 particles. The resolution of the final map
was estimated by observing 0.5 cutoff value of the plot of the Fourier shell
correlation coefficient between two reconstructed maps each built from half of the
data set. The final resolutions of the DENV3–Fab 5J7 complex, DENV at 28 C and
at 37 C were 9, 6 and 7 Å, respectively.
Model fitting. Model fitting of DENV3 control at 28 C was done first, because the
resolution of the map was higher (6 Å) than the DENV3 control at 37 C map
(7 Å). This approach allowed for precise fitting. Although structure of recombinant
DENV3 E-protein ectodomain is known, we did not use it for initial fitting as the
structure does not contain the stem and transmembrane regions. Furthermore, the
DI–DII hinge angle is different between the virus structure and crystal structures.
Because of this, the cryo-EM structure of DENV2 (PDB code: 3J27) was initially
used to fit the map and the residues were later mutated to that of DENV3 strain
863DK. Initial fitting was done manually by using the programme Chimera50 and
the fit was further optimized using the ‘Fit in Map’ function in Chimera. The
amino acid residues of the fitted DENV2 E and membrane proteins were then
mutated to DENV3 sequence and the EoFo loop was replaced by the crystal
structure of DENV3 E protein, as it has a shorter loop than DENV2. Both
procedures were done using COOT51. The molecular dynamic flexible fitting52 was
used together with NAMD53 and VMD54 for cryo-EM map-guided molecular
dynamic simulation to optimize the fit of the molecules. Symmetry restraints were
applied to avoid clashes between neighbouring molecules and a factor of 0.5 was
used to weigh the contribution of the cryo-EM map in the overall potential energy
of the molecular dynamic simulation. The simulation involved 20,000 steps of
minimization followed by 100,000 steps of molecular dynamics before converging
into a stable solution. The final structures were observed to be free of misfits and
clashes by using the O programme55.
The DENV3 control at 28 C structure was then used to fit into the DENV3
control at 37 C (7 Å resolution) and also the Fab 5J7 complex (9 Å resolution)
cryo-EM maps. No obvious structural differences of the E proteins between these
cryo-EM structures were detected. For the fitting of the Fab 5J7 molecules into the
antibody-complexed cryo-EM map, a homology model for Fab 5J7 was built by
using Swiss-model server56 with two human Ab structures (PDB codes 3MA9 and
1DEE) as templates for the Fab 5J7 heavy and light chains, respectively. Only the
variable region of the Fab structure was modelled. The variable regions of the Fab
5J7 heavy and light chains showed a high sequence homology of 78% and 90%,
respectively, with the corresponding variable regions in the aforementioned PDB
starting homology models (Supplementary Fig. 6). Fitting procedure was done in a
similar manner as the DENV3 control.
Structural analysis. We carried out structure and sequence analyses using the
following computer programmes: Gerstein’s accessible surface calculator57 in
StrucTools server (http://helixweb.nih.gov/structbio/basic.html) for calculating the
contact area between two molecules, Multalin58 server for multiple sequence
alignment and LSQ Superpose in COOT for superimposition of protein structures.
Chimera was used for electrostatic potential surface calculation and visualization of
the structures. The amino acid sequences used for comparison were DENV1 strain
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PVP159 (GenBank accession code AEM92304.1), DENV2 strain New Guinea—C
(GenBank accession code AAA42941.1), DENV3 strain 863DK (GenBank
accession code EU081190.1) and DENV4 strain Dominic 1981 (GenBank accession
code AAK01233.1). The DENV structures used for electrostatic potential surface
analyses were the cryo-EM structures of DENV1, DENV2 and DENV4 (PDB
accession codes 4CCT, 3J27 and 4CBF, respectively).
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